MarketCapExport financials
Aeglea BioTherapeutics (AGLE)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Aeglea BioTherapeutics Balance Sheet 2025-2011 | AGLE
Brief overview of Aeglea BioTherapeutics's balance sheet strength
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
Total assets increased by +607.5%, from $109.9 million to $777.8 million. A CAGR near 63.1% points to substantial expansion.
Liability growth of +140.7% trailed asset growth of +607.5%. The funding structure became more resilient.
The equity ratio reached 92% from 76.4%. A high capital share reduces dependence on liabilities.
The cash share moved from 15.4% to 11%. A higher figure generally provides more room in an adverse scenario.
The balance sheet includes a negative accumulated result of -$1.1 billion. It should be assessed alongside historical profits and capital distributions.
Conclusion
Aeglea BioTherapeutics's financial position is positive on balance sheet evidence. Growth in resources has not undermined capital strength.
Annual Balance Sheet Aeglea BioTherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | -30.2 M | -14.7 M | -89.7 M | -18.9 M | -22.5 M | -12.8 M | -47.7 M | -29.3 M | -2.62 M | -4.6 M | - | - |
Long Term Debt |
- | - | - | 4 M | 16 K | 45 K | 31 K | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | - | - | 625 K | 436 K | 319 K | 351 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
3.86 M | 36.6 M | 41.3 M | 6.18 M | 5.84 M | 5.34 M | 4.74 M | 72 K | 111 K | 132 K | 27 K | - | - | - | - |
Total Current Liabilities |
58.7 M | 54.1 M | 32 M | 14.7 M | 20.1 M | 16.4 M | 18.4 M | 10.2 M | 5.63 M | 3.96 M | - | - | - | - | - |
Total Liabilities |
62.5 M | 90.7 M | 73.3 M | 20.8 M | 26 M | 21.8 M | 23.1 M | 10.3 M | 5.74 M | 4.1 M | 2.55 M | 1.06 M | 1.41 M | - | - |
Deferred Revenue |
- | - | - | 517 K | 2.36 M | - | - | - | 20 K | 71 K | - | - | - | - | - |
Retained Earnings |
-1.13 B | -972 M | -764 M | -426 M | -342 M | -276 M | -195 M | -117 M | -72.5 M | -45.3 M | -23.6 M | -12.3 M | -1.94 M | - | - |
Total Assets |
778 M | 608 M | 342 M | 71.1 M | 110 M | 162 M | 83.2 M | 77.7 M | 56.1 M | 67.1 M | 38.7 M | 2.93 M | 4.6 M | - | - |
Cash and Cash Equivalents |
85.7 M | 89.4 M | 189 M | 34.9 M | 15.1 M | 90.1 M | 19.3 M | 22.5 M | 12.8 M | 47.7 M | 29.3 M | 2.62 M | - | - | - |
Book Value |
715 M | 518 M | 269 M | 50.3 M | 83.9 M | 140 M | 60.1 M | 67.4 M | 50.3 M | 63 M | 36.1 M | 1.87 M | 3.18 M | - | - |
Total Shareholders Equity |
715 M | 518 M | 184 M | 50.3 M | 83.9 M | 140 M | 60.1 M | 67.4 M | 50.3 M | 63 M | -22.2 M | -11.5 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Aeglea BioTherapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.82 M | 4 M | 4.16 M | 4.32 M | 4.47 M | 4.61 M | 4.75 M | 4.88 M | 5.01 M | 5.13 M | 4.95 M | 4.7 M | 4.82 M | 4.71 M | 4.87 M | 4.82 M | 372 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
8.05 M | 8.56 M | 7.98 M | 3.86 M | 3.23 M | - | 16.5 M | 36.6 M | 36.2 M | 39.6 M | 39.1 M | 41.3 M | 20.7 M | 21.3 M | 6.16 M | 6.18 M | 6.33 M | 6.69 M | 5.22 M | 5.84 M | 6.55 M | 7.35 M | 7.49 M | 5.34 M | 5.01 M | 4.76 M | 4.84 M | 4.74 M | 4.9 M | 4.86 M | 424 K | 72 K | 81 K | 91 K | 101 K | 111 K | 117 K | 122 K | 127 K | 132 K | 26 K | 16 K | 22 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
48.2 M | 71.9 M | 93.1 M | 62.5 M | 49.5 M | 83.1 M | 87.2 M | 90.7 M | 93.7 M | 61.7 M | 81.9 M | 73.3 M | 65.6 M | 254 M | 18.8 M | 20.8 M | 24 M | 22.6 M | 21.5 M | 26 M | 27 M | 28 M | 39.9 M | 21.8 M | 19.4 M | 20.7 M | 22 M | 23.1 M | 20.3 M | 17.9 M | 12.2 M | 10.3 M | 7.6 M | 6.27 M | 5.87 M | 5.74 M | 4.99 M | 4.54 M | 4.08 M | 4.1 M | 3.86 M | 3.38 M | 3.84 M | 2.55 M | 2.55 M | 2.55 M | 2.55 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | 3.27 M | 2.64 M | 517 K | 2.68 M | 2.66 M | 2.81 M | 3.58 M | 4.79 M | 5.53 M | 19.2 M | - | - | - | - | - | - | - | - | - | - | - | - | 20 K | 50 K | 71 K | 51 K | 71 K | 181 K | 71 K | 71 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.33 B | -1.23 B | -1.2 B | -1.13 B | -1.07 B | -1.05 B | -1.02 B | -972 M | -916 M | -847 M | -808 M | -764 M | -701 M | -661 M | -444 M | -426 M | -407 M | -389 M | -366 M | -342 M | -321 M | -301 M | -294 M | -276 M | -253 M | -235 M | -214 M | -195 M | -174 M | -152 M | -134 M | -117 M | -102 M | -90 M | -80.6 M | -72.5 M | -66 M | -58.2 M | -51.5 M | -45.3 M | -39.8 M | -33.6 M | -28.1 M | -23.6 M | -23.6 M | -23.6 M | -23.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
1.1 B | 1.17 B | 764 M | 778 M | 505 M | 539 M | 570 M | 608 M | 421 M | 436 M | 488 M | 342 M | 207 M | 244 M | 52.5 M | 71.1 M | 91.6 M | 107 M | 83.2 M | 110 M | 129 M | 147 M | 164 M | 162 M | 156 M | 173 M | 64.8 M | 83.2 M | 100 M | 117 M | 129 M | 77.7 M | 71.3 M | 79.7 M | 49.8 M | 56.1 M | 60.5 M | 67.1 M | 61.3 M | 67.1 M | 72.1 M | 77.3 M | 35.5 M | 38.7 M | 38.7 M | 38.7 M | 38.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
82.7 M | 162 M | 97.2 M | 85.7 M | 64.9 M | 81.7 M | 48.5 M | 89.4 M | 71.6 M | 45.5 M | 228 M | 189 M | 91.9 M | 237 M | 36.6 M | 36.4 M | 40.5 M | 37.5 M | 14.6 M | 17 M | 24.7 M | 34.8 M | 80.2 M | 91.9 M | 54.2 M | 65.7 M | 12.6 M | 19.3 M | 24.5 M | 25.4 M | 85.6 M | 22.5 M | 14.5 M | 20.6 M | 10.8 M | 12.8 M | 13.2 M | 26.9 M | 16.8 M | 47.7 M | 49.5 M | 70.6 M | 24 M | 29.3 M | 29.3 M | 29.3 M | 29.3 M | 2.62 M | - | - | - | 4.6 M | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
1.05 B | 1.1 B | 671 M | 715 M | 455 M | 456 M | 483 M | 518 M | 327 M | 374 M | 406 M | 269 M | 142 M | -10 M | 33.7 M | 50.3 M | 67.6 M | 84.2 M | 61.7 M | 83.9 M | 102 M | 119 M | 124 M | 140 M | 136 M | 152 M | 42.8 M | 60.1 M | 79.8 M | 99.6 M | 116 M | 67.4 M | 63.7 M | 73.4 M | 43.9 M | 50.3 M | 55.5 M | 62.6 M | 57.2 M | 63 M | 68.2 M | 73.9 M | 31.7 M | 36.1 M | 36.1 M | 36.1 M | 36.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
1.05 B | 1.1 B | 671 M | 715 M | 455 M | 456 M | 483 M | 518 M | 327 M | 374 M | 152 M | 184 M | -245 M | -207 M | 33.7 M | 50.3 M | 67.6 M | 84.2 M | 61.7 M | 83.9 M | 102 M | 119 M | 124 M | 140 M | 136 M | 152 M | 42.8 M | 60.1 M | 79.8 M | 99.6 M | 116 M | 67.4 M | 63.7 M | 73.4 M | 43.9 M | 50.3 M | 55.5 M | 62.6 M | 57.2 M | 63 M | 68.2 M | 73.9 M | -26.6 M | -22.2 M | -22.2 M | -22.2 M | -22.2 M | -11.5 M | - | - | - | -1.27 M | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Aeglea BioTherapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
Britain
Cayman-islands
Danmark
China
Australia